Q32 Bio Raises $10.5M, Extends Cash Runway to Q4 2027
Q32 Bio raised $10.5M via RDO and sold ADX-097 to Akebia, securing $48.3M cash at year-end plus downstream milestones, extending runway into Q4 2027. The company enrolled 33 patients in Part B of its SIGNAL-AA Phase 2a trial and expects 36-week bempikibart topline data by mid-2026.
1. Clinical Trial Progress
Completed enrollment in Part B of the SIGNAL-AA Phase 2a trial with 33 patients receiving a 36-week bempikibart regimen and follow-up to 52 weeks; 36-week topline data is expected by mid-2026. Early pharmacokinetic analysis shows steady-state drug levels are reached nine weeks faster due to a loading regimen, coinciding with emerging signs of clinical activity.
2. Financing and Asset Sale
Q32 Bio completed a registered direct offering raising $10.5 million via the sale of 1,666,679 common shares and pre-funded warrants at $3.90 per share, and sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for guaranteed near-term milestone payments.
3. Financial Position and Runway
Cash and cash equivalents stood at $48.3 million as of December 31, 2025, and combined with RDO proceeds and milestone payments from the ADX-097 sale, are expected to fund operations into the fourth quarter of 2027.